SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma

Giovanni Barosi, Giampaolo Merlini, Atto Billio, Mario Boccadoro, Paolo Corradini, Monia Marchetti, Massimo Massaia, Patrizia Tosi, Antonio Palumbo, Michele Cavo, Sante Tura

Research output: Contribution to journalArticle

Abstract

In this project, we produced drug-specific recommendations targeting the use of new agents for multiple myeloma (MM). We used the GRADE (Grades of Recommendation, Assessment, Development, and Evaluation) system which separates the judgments on quality of evidence from the judgment about strength of recommendations. We recommended thalidomide and bortezomib in MM patients candidates to autologous stem cell transplantation (ASCT) (weak positive). We did not recommend novel agents as maintenance therapy after ASCT (weak negative). In patients not candidate to ASCT, thalidomide or bortezomib (strong positive) associated with melphalan and prednisone were recommended. In these patients, no specific course of action could be recommended as for maintenance therapy. In patients who are refractory or relapsing after first-line therapy, we recommended bortezomib and pegylated liposomal doxorubicin, or lenalidomide and dexamethasone combinations (weak positive).

Original languageEnglish
Pages (from-to)875-888
Number of pages14
JournalAnnals of Hematology
Volume91
Issue number6
DOIs
Publication statusPublished - Jun 2012

Fingerprint

Thalidomide
Multiple Myeloma
Stem Cell Transplantation
Guidelines
Melphalan
Therapeutics
Prednisone
Dexamethasone
Bortezomib
lenalidomide
Pharmaceutical Preparations

Keywords

  • Bortezomib
  • GRADE
  • Guideline
  • Lenalidomide
  • Multiple myeloma
  • Recommendations
  • Thalidomide

ASJC Scopus subject areas

  • Hematology

Cite this

SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma. / Barosi, Giovanni; Merlini, Giampaolo; Billio, Atto; Boccadoro, Mario; Corradini, Paolo; Marchetti, Monia; Massaia, Massimo; Tosi, Patrizia; Palumbo, Antonio; Cavo, Michele; Tura, Sante.

In: Annals of Hematology, Vol. 91, No. 6, 06.2012, p. 875-888.

Research output: Contribution to journalArticle

Barosi, Giovanni ; Merlini, Giampaolo ; Billio, Atto ; Boccadoro, Mario ; Corradini, Paolo ; Marchetti, Monia ; Massaia, Massimo ; Tosi, Patrizia ; Palumbo, Antonio ; Cavo, Michele ; Tura, Sante. / SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma. In: Annals of Hematology. 2012 ; Vol. 91, No. 6. pp. 875-888.
@article{3ef4ccb6386b44a9bb82978b89ad3607,
title = "SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma",
abstract = "In this project, we produced drug-specific recommendations targeting the use of new agents for multiple myeloma (MM). We used the GRADE (Grades of Recommendation, Assessment, Development, and Evaluation) system which separates the judgments on quality of evidence from the judgment about strength of recommendations. We recommended thalidomide and bortezomib in MM patients candidates to autologous stem cell transplantation (ASCT) (weak positive). We did not recommend novel agents as maintenance therapy after ASCT (weak negative). In patients not candidate to ASCT, thalidomide or bortezomib (strong positive) associated with melphalan and prednisone were recommended. In these patients, no specific course of action could be recommended as for maintenance therapy. In patients who are refractory or relapsing after first-line therapy, we recommended bortezomib and pegylated liposomal doxorubicin, or lenalidomide and dexamethasone combinations (weak positive).",
keywords = "Bortezomib, GRADE, Guideline, Lenalidomide, Multiple myeloma, Recommendations, Thalidomide",
author = "Giovanni Barosi and Giampaolo Merlini and Atto Billio and Mario Boccadoro and Paolo Corradini and Monia Marchetti and Massimo Massaia and Patrizia Tosi and Antonio Palumbo and Michele Cavo and Sante Tura",
year = "2012",
month = "6",
doi = "10.1007/s00277-012-1445-y",
language = "English",
volume = "91",
pages = "875--888",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma

AU - Barosi, Giovanni

AU - Merlini, Giampaolo

AU - Billio, Atto

AU - Boccadoro, Mario

AU - Corradini, Paolo

AU - Marchetti, Monia

AU - Massaia, Massimo

AU - Tosi, Patrizia

AU - Palumbo, Antonio

AU - Cavo, Michele

AU - Tura, Sante

PY - 2012/6

Y1 - 2012/6

N2 - In this project, we produced drug-specific recommendations targeting the use of new agents for multiple myeloma (MM). We used the GRADE (Grades of Recommendation, Assessment, Development, and Evaluation) system which separates the judgments on quality of evidence from the judgment about strength of recommendations. We recommended thalidomide and bortezomib in MM patients candidates to autologous stem cell transplantation (ASCT) (weak positive). We did not recommend novel agents as maintenance therapy after ASCT (weak negative). In patients not candidate to ASCT, thalidomide or bortezomib (strong positive) associated with melphalan and prednisone were recommended. In these patients, no specific course of action could be recommended as for maintenance therapy. In patients who are refractory or relapsing after first-line therapy, we recommended bortezomib and pegylated liposomal doxorubicin, or lenalidomide and dexamethasone combinations (weak positive).

AB - In this project, we produced drug-specific recommendations targeting the use of new agents for multiple myeloma (MM). We used the GRADE (Grades of Recommendation, Assessment, Development, and Evaluation) system which separates the judgments on quality of evidence from the judgment about strength of recommendations. We recommended thalidomide and bortezomib in MM patients candidates to autologous stem cell transplantation (ASCT) (weak positive). We did not recommend novel agents as maintenance therapy after ASCT (weak negative). In patients not candidate to ASCT, thalidomide or bortezomib (strong positive) associated with melphalan and prednisone were recommended. In these patients, no specific course of action could be recommended as for maintenance therapy. In patients who are refractory or relapsing after first-line therapy, we recommended bortezomib and pegylated liposomal doxorubicin, or lenalidomide and dexamethasone combinations (weak positive).

KW - Bortezomib

KW - GRADE

KW - Guideline

KW - Lenalidomide

KW - Multiple myeloma

KW - Recommendations

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=84862651965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862651965&partnerID=8YFLogxK

U2 - 10.1007/s00277-012-1445-y

DO - 10.1007/s00277-012-1445-y

M3 - Article

C2 - 22476884

AN - SCOPUS:84862651965

VL - 91

SP - 875

EP - 888

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 6

ER -